{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:22:46Z","timestamp":1786760566843,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Five Phase 3 bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) clinical studies demonstrated that the efficacy of B\/F\/TAF was non-inferior to dolutegravir (DTG)\u200a+\u200a2 NRTIs. We retrospectively assessed drug adherence and effect on virologic outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Studies (NCT02607930, NCT02607956, NCT03547908, NCT02603120 and NCT03110380) were double-blind, placebo-controlled and enrolled treatment-na\u00efve or virologically suppressed adults. Adherence was calculated by pill count from returned pill bottles; virologic outcome was assessed by last on-treatment HIV-1 RNA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Altogether, 2622 participants (B\/F\/TAF: n\u200a=\u200a1306; DTG\u200a+\u200a2 NRTIs: n\u200a=\u200a1316) were categorized as having high (\u226595%), intermediate (\u226585% to &amp;lt;95%) or low (&amp;lt;85%) adherence. Through Week 48, low adherence was observed in 46 (3.5%) participants in the B\/F\/TAF group (78% median adherence) and 69 (5.2%) in the DTG\u200a+\u200a2 NRTI group (80% median adherence). Overall, 1287 (98.5%) participants in the B\/F\/TAF group and 1292 (98.2%) in the DTG\u200a+\u200a2 NRTI group had virologic suppression (VS; HIV-1 RNA\u200a&amp;lt;\u200a50\u2005copies\/mL) through Week 48. VS in participants with low adherence versus high or intermediate adherence was similar in the B\/F\/TAF group, but lower in the DTG\u200a+\u200a2 NRTI group (P\u200a\u2264\u200a0.002). Similar results were observed at Weeks 96 and 144. Two participants (&amp;lt;95% adherence) in the DTG\u200a+\u200a2 NRTI group receiving DTG and abacavir\/lamivudine developed M184V; there was no treatment-emergent resistance to B\/F\/TAF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Participants with suboptimal (&amp;lt;85%) adherence to B\/F\/TAF maintained high levels of VS, whereas suboptimal DTG\u200a+\u200a2 NRTI adherence was associated with lower VS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae407","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:07:07Z","timestamp":1731946027000},"page":"281-291","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy"],"prefix":"10.1093","volume":"80","author":[{"given":"Kristen","family":"Andreatta","sequence":"first","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wohl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"D\u2019Antoni","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Biostatistics Virology, Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T","family":"Hindman","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"2025010309474219800_dkae407-B1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00002030-200003100-00008","article-title":"Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population","volume":"14","author":"Bangsberg","year":"2000","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00042560-200205010-00014","article-title":"Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients","volume":"30","author":"de Olalla","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025010309474219800_dkae407-B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"2025010309474219800_dkae407-B4","first-page":"1112","article-title":"Virological failure and adherence to antiretroviral therapy in HIV-infected patients","volume":"12","author":"Rodriguez-Rosado","year":"1998","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B5","author":"EACS"},{"key":"2025010309474219800_dkae407-B6","doi-asserted-by":"publisher","first-page":"e3361","DOI":"10.1097\/MD.0000000000003361","article-title":"Adherence to antiretroviral therapy and virologic failure: a meta-analysis","volume":"95","author":"Bezabhe","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025010309474219800_dkae407-B7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/apc.2014.0165","article-title":"Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types","volume":"29","author":"Gordon","year":"2015","journal-title":"AIDS Patient Care STDS"},{"key":"2025010309474219800_dkae407-B8","doi-asserted-by":"publisher","first-page":"e7196","DOI":"10.1371\/journal.pone.0007196","article-title":"The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy","volume":"4","author":"Rosenblum","year":"2009","journal-title":"PLoS One"},{"key":"2025010309474219800_dkae407-B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/QAI.0b013e318050d8c2","article-title":"HIV-infected patients receiving lopinavir\/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%","volume":"45","author":"Shuter","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025010309474219800_dkae407-B10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression","volume":"43","author":"Bangsberg","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025010309474219800_dkae407-B11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025010309474219800_dkae407-B12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/QAI.0000000000000643","article-title":"Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy","volume":"69","author":"Viswanathan","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025010309474219800_dkae407-B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","article-title":"Antiretroviral adherence level necessary for HIV viral suppression using real-world data","volume":"82","author":"Byrd","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025010309474219800_dkae407-B14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/QAD.0000000000003234","article-title":"Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs","volume":"36","author":"Stover","year":"2022","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025010309474219800_dkae407-B16","author":"Gilead Sciences"},{"key":"2025010309474219800_dkae407-B17","author":"Gilead Sciences"},{"key":"2025010309474219800_dkae407-B18","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025010309474219800_dkae407-B19","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, Phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"2025010309474219800_dkae407-B20","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2025010309474219800_dkae407-B21","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, Phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2025010309474219800_dkae407-B22","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, Phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2025010309474219800_dkae407-B23","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025010309474219800_dkae407-B24","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: Week 144 results from two randomised, double-blind, multicentre, Phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"2025010309474219800_dkae407-B25","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, Phase 3, non-inferiority trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"2025010309474219800_dkae407-B26","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: Week 96 results from a randomised, double-blind, multicentre, Phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"2025010309474219800_dkae407-B27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"2025010309474219800_dkae407-B28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jac\/dkn020","article-title":"Forgiveness of non-adherence to HIV-1 antiretroviral therapy","volume":"61","author":"Shuter","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025010309474219800_dkae407-B30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1089\/aid.2008.0141","article-title":"Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study","volume":"24","author":"Martin","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025010309474219800_dkae407-B31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1086\/339074","article-title":"The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials","volume":"34","author":"Mannheimer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025010309474219800_dkae407-B32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1086\/427192","article-title":"Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"},{"key":"2025010309474219800_dkae407-B34","doi-asserted-by":"publisher","first-page":"e12598","DOI":"10.1371\/journal.pone.0012598","article-title":"Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk","volume":"5","author":"Lingappa","year":"2010","journal-title":"PLoS One"},{"key":"2025010309474219800_dkae407-B35","doi-asserted-by":"publisher","first-page":"e9495","DOI":"10.1097\/MD.0000000000009495","article-title":"Predicting poor adherence to antiretroviral therapy among treatment-naive veterans infected with human immunodeficiency virus","volume":"97","author":"Cheng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025010309474219800_dkae407-B36","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/QAI.0000000000003280","article-title":"Impact of treatment adherence on efficacy of dolutegravir + lamivudine and dolutegravir + tenofovir disoproxil fumarate\/emtricitabine: pooled Week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies","volume":"94","author":"Fernvik","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025010309474219800_dkae407-B37","doi-asserted-by":"publisher","first-page":"23259582221140208","DOI":"10.1177\/23259582221140208","article-title":"Real world data on forgiveness to uncomplete adherence to bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025010309474219800_dkae407-B38","doi-asserted-by":"publisher","first-page":"23259582221101815","DOI":"10.1177\/23259582221101815","article-title":"Adherence to and forgiveness of 3TC\/DTG in a real-world cohort","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025010309474219800_dkae407-B39","article-title":"ANRS 177 DUETTO randomized, open-label and multicentric trial evaluating the non-inferiority of maintenance antiretroviral dual therapy taken 4 consecutive days per week versus dual therapy 7\/7 days per week [poster eP.A.106]","author":"Landman"},{"key":"2025010309474219800_dkae407-B40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/jpm13040583","article-title":"Intermittent bictegravir\/emtricitabine\/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV","volume":"13","author":"Sellem","year":"2023","journal-title":"J Pers Med"},{"key":"2025010309474219800_dkae407-B41","article-title":"The discovery of S\/GSK1349572: a once daily next generation integrase inhibitor with a superior resistance profile [abstract 55]","author":"Johns"},{"key":"2025010309474219800_dkae407-B42","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010309474219800_dkae407-B43","author":"ViiV Healthcare"},{"key":"2025010309474219800_dkae407-B44","doi-asserted-by":"publisher","first-page":"e02406-20","DOI":"10.1128\/AAC.02406-20","article-title":"Long dissociation of bictegravir from HIV-1 integrase-DNA complexes","volume":"65","author":"White","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010309474219800_dkae407-B45","author":"ViiV Healthcare"},{"key":"2025010309474219800_dkae407-B46","first-page":"483","article-title":"Patterns of adherence in bictegravir- and dolutegravir-based regimens","volume":"28","author":"Sax","year":"2020","journal-title":"Top Antivir Med"},{"key":"2025010309474219800_dkae407-B47","author":"ViiV Healthcare"},{"key":"2025010309474219800_dkae407-B48","author":"ViiV Healthcare"},{"key":"2025010309474219800_dkae407-B49","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"key":"2025010309474219800_dkae407-B50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jama.2015.10516","article-title":"Missing data: how to best account for what is not known","volume":"314","author":"Newgard","year":"2015","journal-title":"JAMA"},{"key":"2025010309474219800_dkae407-B51","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1007\/s10461-020-02937-8","article-title":"Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US","volume":"24","author":"Benson","year":"2020","journal-title":"AIDS Behav"},{"key":"2025010309474219800_dkae407-B52","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","article-title":"Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"},{"key":"2025010309474219800_dkae407-B53","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000003783","article-title":"A study of the pharmacokinetics, safety, and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed pregnant women with HIV","volume":"38","author":"Zhang","year":"2024","journal-title":"AIDS"},{"key":"2025010309474219800_dkae407-B54","article-title":"Efficacy, safety, and PK of BIC\/FTC\/TAF in adults with HIV and tuberculosis on rifampicin at Week 24 [oral 211]","author":"Naidoo"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/281\/60741914\/dkae407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/281\/60741914\/dkae407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:48:02Z","timestamp":1735897682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/1\/281\/7903192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae407","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,18]]}}}